Smooth muscle contractility and protein tyrosine phosphorylation

Molecular and Cellular Biochemistry

Volumn 176, Issue 1-2, 1997, Pages 47-51

  Srivastava, Ashok K ^a   St Louis, Jean ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Growth factors; Tyrosine kinases; Vanadate

Indexed keywords

CALCIUM ION; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; GENISTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; TYRPHOSTIN; VANADIC ACID; VASOACTIVE AGENT;

ANIMAL CELL; CALCIUM CELL LEVEL; ENZYME INHIBITION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE CONTRACTION;

ANIMALS; CALCIUM; ENZYME INHIBITORS; GUINEA PIGS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; RATS; SWINE; VANADATES;

ANIMALIA;

EID: 0030777874     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006818810678     Document Type: Review

References (40)

1. Somylo AP, Somlyo AV: Signal transduction and regulation in smooth muscle. Nature 372: 232-236, 1994
2. Kamm KE, Stull JT: Regulation of smooth muscle contractile elements by second messengers. Ann Rev Physiol 51: 299-314, 1989
3. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K: Regulation of myosine phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245-248, 1996
4. Yang S-G, Saifeddine M, Hollenberg MD: Tyrosine kinase inhibitors and the contractile action of epidermal growth factor urogastrone and other agonists in gastric smooth muscle. Can J Physiol Pharmacol 70: 85-93, 1992
5. Sauro MD, Thomas B: Tyrphostin attenuates platelet-derived growth factros-induced contraction in smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Expt Therapeut 267: 1119-11254, 1993
6. Saifeddine M, Laniyonu A, Yang S-G, Hollenberg MD: Tyrosine kinase inhibitors and the contractile actions of angiotensin II in vascular tissue. Pharmacol Commun 1: 177-184, 1992
7. Yang S-G, Saifeddine M, Laniyonu A, Hollenberg MD: Distinct signal transduction pathways for angiotensin II in guinea pig gastric smooth muscle: Differential blockade by indomethacin and tyrosine kinase inhibitors. J Pharm Exptl Ther 264: 958-967, 1993
8. Sauro MD, Sudakow R, Burns S: In vivo effects of angiotensin II on vascular smooth muscle contraction and blood pressure are mediated through a protein tyrosine kinase-dependent mechanism. J Pharmacol Exptl Therap 277: 1744-1750, 1996
9. DiSalvo J, Steusloff A, Semenchuk L, Satoh S, Koloquist K, Pfitzer G: Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 190: 968-974, 1993
10. Laniyone AA, Saifeddine M, Yang SG, Hollenberg MH: Tyrosine kinase inhibitors and the contractile action of G-protein-linked vascular agonists. Can J Physiol Pharmacol 72: 1075-1085, 1994
11. Hollenberg MD: Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends in Pharmacol Sci 15: 108-114, 1994
12. Toma C, Jensen PE, Prieto D, Hughes A, Mulvany MJ, Aalkjaer C: Effect of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries. Br J Pharmacol 114: 1266-1272, 1995
13. Hollenberg MD: The actions of growth factors in smooth muscle systems. Life Sciences 54: 223-235, 1993
14. Wjetunge S, Aalkjaer C, Schachter M, Hughes AD: Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun 181: 1620-1623, 1992
15. 2+ entry by tyrosine kinase inhibitors. J Biol Chem 268: 9945-9948, 1993
16. Semenchuk LA, DiSalvo J: Receptor activated increase in intracellular calcium and protein tyrosine phosphorylation in vascular smooth muscle cells. FEBS Lett 370: 127-130, 1995
17. 8]-vasopressin-activated increases in protein tyrosine phosphorylation and cellular calcium in A7 X5 aortic smooth muscle cells. Arch Biochem Biophys 270-280, 1996
18. 2+];) transients in vascular muscle cells. Hypertension 27: 1097-1103, 1996
19. 2+ in human fibroblasts. J Biol Chem 259: 8066-8069, 1984
20. Morris JD, Metcalfe JC, Smith GA, Hesketch TR, Taylor MU: Some mitogens cause rapid increases in free calcium in fibroblasts. FEBS Lett 169: 189-193, 1984
21. Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA Jr, Alexander RW: Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest 75: 1083-1086, 1985
22. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC: Vasoconstriction: a new activity for platelet derived growth factor. Science 232: 87-90, 1986
23. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
24. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kineses. J Biol Chem 262: 5592-5595, 1987
25. Levitzki A, Gilon C: Tyrphostins as molecular tools and potential therapeutic drugs. Trends Pharmacol Sci 12: 171-174, 1991
26. Ozaki H, Urakawa N: Effect of vanadate on mechanical responses and Na-K pump in vascular smooth muscle. Eur J Pharmacol 68: 339-347, 1980
27. Shimada T, Shimamura K, Sunano S: Effects of sodium vanadate on various types of vascular smooth muscles. Blood Vessels 23: 113-124, 1986
28. Sanchez-Ferrer CE, Marln J, Lluch M, Valverde A, Salaiees M: Actions of vanadate on vascular tension and sodium pump activity in cat isolated cerebral and femoral arteries. Br J Pharmacol 93: 53-60, 1988
29. Hudgins PM, Bond GH: Alteration by vanadate of contractility in vascular and intestinal smooth muscle preparations. Pharmacology 23: 156-164, 1981
30. Nayler RA, Sparrow MP: Mechanism of vanadate-induced contraction of airways smooth muscle of the guinea-pig. Br J Pharmacol 80: 163-172, 1983
31. Sunano S, Kato S, Moriyama K, Shimamura K: Influences of sodium on the contractile action of vanadate in depolarized vas deferens and ureter of the guinea-pig. Arch Int Pharmacodyn Therap 293: 196-208, 1988
32. Candura SM, Manzo L, Marraccini P, Coccini T, Tonini M: Investigation into vanadate-induced potentiation of smooth muscle contractility in the rabbit isolated ileum. Life Sci 54: 237-244, 1993
33. Swarup G, Cohen S, Garbers DL: Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107: 1104-1109, 1982
34. DiSalvo J, Semenchuk LA, Lauer J: Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch Biochem Biophys 304: 386-391, 1993
35. St-Louis J, Sicotte B, Breton E, Srivastava AK: Vanadate-induced smooth muscle contraction and protein tyrosine phosphorylation is impaired in pregnancy. J Mol Cell Cardiol 27: 104 (abstract), 1995
36. Posner BI, Faure R, Burgess JW, Beavan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994
37. Laniyonu A, Saifeddin M, Ahmad S, Hollenberg MD: Modulation of vascular and smooth muscle contractility by pervanadate. Brit J Pharmacol 113: 403-410, 1994
38. St-Louis J, Sicotte B, Breton E, Srivastava AK: Contractile effects of vanadate on aorta rings from virgin and pregnant rats. Mol Cell Biochem 153: 145-150, 1995
39. Srivastava AK: Protein tyrosine phosphorylation in cardiovascular system. Mol Cell Biochem 149/150: 87-94, 1995
40. Wijetunge S, Hugher AP: Effect of platelet derived growth factor on voltage operated calcium channels in rabbit isolated ear artery cells. Br J Pharmacol 115: 534-538, 1995